A biologic is produced inside living system, like a microorganism, plant or animal cell, or both. The majority of biologics are huge, complex compounds or molecule mixtures. Recombinant DNA technology is used to make several biologics. Biologics are made from living systems that can be sensitive to even modest modifications in the manufacturing process. Small variations in the manufacturing process can have a big impact on the final biologic's composition and, more crucially, how it works in the body.
Any molecule created by living beings is referred to as a biomolecule. As a result, the vast majority of them are organic molecules. Polysaccharides, amino acids and proteins, nucleic acids (DNA and RNA), and lipids are the four major types of macromolecules found in and produced by living organisms. Over the last two decades, there has been a clear shift away from traditional chemically synthesized small molecule medications and toward large molecule biological drugs or biopharmaceuticals. Despite the fact that many analysts agree on this trend, it is unknown which biomolecules the pharmaceutical industry is currently using for biopharmaceuticals and which biomolecules are in their drug development pipelines that may become the next generation of biopharmaceuticals.
“Antibody-drug cell therapy products when the active ingredient is taken or synthesised from a biological source” are biotherapeutics. Biotherapeutics has become an important aspect of modern medicine, and it is increasingly being utilized to treat and prevent major illnesses, infections, and diseases.
Title : Extracellular vesicles as delivery vehicles of therapeutic compounds
Stefania Raimondo, University of Palermo, Italy
Title : EU GMP annex1 barrier system and PIC/s annex 2A on cell and gene therapy
Richard Denk, SKAN AG, Switzerland
Title : Role of nanoformulations in treating Cystic Fibrosis
Bhupendra Gopalbhai Prajapati, Ganpat University, India
Title : Dual GIP/GLP-1 receptor stimulation in treatment of type 2 diabetes mellitus – The ground-breaking 'twincretin' approach
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Pathology and patient safety: The vital role of electronic medical record and pathology informatics in error reduction and precision medicine
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : mRNA-based systemically delivered directed gene therapy using nanomaterials
A C Matin, Stanford University, United States
Title : Colon-specific scallop hydrolysates/Κ-carrageenan hydrogel loaded with curcumin alleviates dss-induced colitis through modulation of inflammatory cytokines and gut microbiota
Hai Tao Wu, Dalian Polytechnic University, China
Title : Mucoadhesive electrospun fibrous systems for the fast and sustained delivery of drugs
Luis Jesus Villarreal Gomez, Autonomous University of Baja California, Mexico
Title : General and local anaesthetic agents: An analysis of their safety data
Francesca Gargano, Campus Bio-Medico University of Rome, Italy
Title : 15,16-dihydrotanshinone-I-laden PLGA-co-PEG nanoparticles are potential therapeutic agents for the treatment of colorectal cancer by targeting the β-catenin/CD36 axis
Kwan Hiu Yee, Hong Kong Baptist University, China